3-Hydroxymorphinan

From Wikipedia, the free encyclopedia
Jump to: navigation, search
3-Hydroxymorphinan
3-Hydroxymorphinan.svg
Systematic (IUPAC) name
(±)-morphinan-3-ol
Clinical data
Legal status
?
Pharmacokinetic data
Bioavailability 18%
Identifiers
CAS number 1531-12-0 N
ATC code None
ChemSpider 16735936 YesY
Chemical data
Formula C16H21NO 
Mol. mass 243.344 g/mol
 N (what is this?)  (verify)

3-Hydroxymorphinan (3-HM), or morphinan-3-ol, is a psychoactive drug of the morphinan family.[1] It is the racemic version of norlevorphanol.

The dextrorotatory stereoisomer of the compound is an active metabolite of dextromethorphan, dextrorphan, and 3-methoxymorphinan,[2] and similarly to them has potent neuroprotective and neurotrophic effects on LTS- and MPTP-treated dopaminergic neurons of the nigrostriatal pathway,[3][4] but notably without producing any neuropsychotoxic side effects (e.g., dissociation or hallucinations) or having any anticonvulsant actions.[5][6] It does not seem to bind to the NMDA receptor,[6] and instead, its neuroprotective properties appear result from inhibition of glutamate release via the suppression of presynaptic voltage-dependent Ca2+ entry and protein kinase C activity.[7] In any case, as such, the compound has been investigated as a potential antiparkinsonian agent. A prodrug, GCC1290K, has been developed on account of 3-HM's poor bioavailability (18%), and a New Drug Application has been approved for it by the United States Food and Drug Administration.[6] It is currently undergoing clinical trials for the treatment of Parkinson's disease.[6]

3-HM's levorotatory stereoisomer, norlevorphanol, in contrast to (+)-3-HM, is an opioid analgesic.[8] It was never marketed as such however, probably due to a combination of the facts that norlevorphanol has low bioavailability and that its potency is diminished compared to its N-methylated analogue levorphanol.[9]

See also[edit]

References[edit]

  1. ^ C. R Ganellin; D. J Triggle; F.. Macdonald (1997). Dictionary of pharmacological agents. CRC Press. p. 1378. ISBN 978-0-412-46630-4. Retrieved 29 November 2011. 
  2. ^ Jacqz-Aigrain E, Cresteil T (1992). "Cytochrome P450-dependent metabolism of dextromethorphan: fetal and adult studies". Developmental Pharmacology and Therapeutics 18 (3-4): 161–8. PMID 1306804. 
  3. ^ Zhang W, Qin L, Wang T, et al. (March 2005). "3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity". The FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology 19 (3): 395–7. doi:10.1096/fj.04-1586fje. PMID 15596482. 
  4. ^ Zhang W, Shin EJ, Wang T, et al. (December 2006). "3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro". The FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology 20 (14): 2496–511. doi:10.1096/fj.06-6006com. PMID 17142799. 
  5. ^ Shin EJ, Lee PH, Kim HJ, Nabeshima T, Kim HC (January 2008). "Neuropsychotoxicity of abused drugs: potential of dextromethorphan and novel neuroprotective analogs of dextromethorphan with improved safety profiles in terms of abuse and neuroprotective effects". Journal of Pharmacological Sciences 106 (1): 22–7. doi:10.1254/jphs.fm0070177. PMID 18198471. 
  6. ^ a b c d Shin EJ, Bach JH, Lee SY, et al. (2011). "Neuropsychotoxic and neuroprotective potentials of dextromethorphan and its analogs". Journal of Pharmacological Sciences 116 (2): 137–48. doi:10.1254/jphs.11r02cr. PMID 21606622. 
  7. ^ Lin TY, Lu CW, Wang SJ (July 2009). "Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan". Neurochemistry International 54 (8): 526–34. doi:10.1016/j.neuint.2009.02.012. PMID 19428798. 
  8. ^ Dictionary of organic compounds. London: Chapman & Hall. 1996. ISBN 0-412-54090-8. 
  9. ^ Bentham Science Publishers (April 1995). Current Medicinal Chemistry. Bentham Science Publishers. p. 425. Retrieved 29 November 2011.